- Home
- FIG vs KYMR Comparison
FIG vs KYMR Comparison
Compare FIG & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIG | KYMR |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 10.6B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FIG | KYMR |
|---|---|---|
| Price | $23.06 | $115.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 26 |
| Target Price | $50.50 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 13.5M | 583.8K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.80 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,055,788,000.00 | $39,211,000.00 |
| Revenue This Year | $31.18 | $10.61 |
| Revenue Next Year | $20.22 | $8.17 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.96 | N/A |
| 52 Week Low | $16.60 | $47.86 |
| 52 Week High | $71.41 | $130.05 |
Technical Indicators
Market Signals| Indicator | FIG | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 46.68 | 44.19 |
| Support Level | $20.28 | $110.82 |
| Resistance Level | $24.76 | $120.37 |
| Average True Range (ATR) | 1.54 | 4.83 |
| MACD | -0.49 | -1.16 |
| Stochastic Oscillator | 25.01 | 17.85 |
Price Performance
Historical ComparisonAbout FIG Figma Inc.
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.